Keep pulling the thread on Alex Cohen.
Hello Patient has raised a $22.5 million Series A funding round.
Hello Patient's $22.5 million Series A was led by Scale Venture Partners, with participation from existing investor 8VC.
Alex Cohen states that the biggest challenge in building Hello Patient is the inherent unreliability of current AI agents in consistently following complex workflows.
Tesamorelin, an FDA-approved peptide for treating visceral fat in HIV patients, is also used off-label as a longevity drug.
Hello Patient provides an omni-channel conversational AI platform for healthcare practices, covering phone calls, text messages, and a website chatbot for patient-facing communication.
Alex Cohen believes OpenAI's models are the best-in-class and smartest models currently available on the market.
Hello Patient's seed round investors included 8VC, Bling Capital, and Max Ventures.
New strategic investors in Hello Patient's Series A round include Alumni Ventures, Lord David Pryor (former chairman of the NHS), and Remus Capital.
Hello Patient found that models from Google (Gemini) and Anthropic (Claude) have latency issues that make them too slow for real-time phone call applications.
Alex Cohen predicts that Artificial General Intelligence (AGI) is still five to seven years away.
Hello Patient's technology stack for voice AI uses Cartesia or ElevenLabs for voice synthesis and Deepgram for transcription.
Hello Patient's primary goal for the next 12 months is to scale its platform to be live in thousands of healthcare clinics.